Development of Safer,Live Attenuated Rift Valley Fever Vaccines
开发更安全的裂谷热减毒活疫苗
基本信息
- 批准号:9091408
- 负责人:
- 金额:$ 19.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-17 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAfrica South of the SaharaAgeAgricultureAmino AcidsAnimalsAntiviral ResponseArthralgiaAttenuatedAttenuated VaccinesBioterrorismBunyaviridaeCategoriesCattleCell Culture TechniquesCell membraneCenters for Disease Control and Prevention (U.S.)Cessation of lifeContainmentCountryCulicidaeCultured CellsDataDevelopmentDiseaseDisease OutbreaksDouble-Stranded RNAEconomicsEgyptEncephalitisEndemic DiseasesEpidemicExhibitsFamilyFarming environmentFeverFluorouracilGeneral PopulationGeneticGenetic TranscriptionGenomeGenus PhlebovirusGlycoproteinsHeadacheHealthHealth StatusHepatitisHumanHumoral ImmunitiesImmune responseImmunityImmunizationImmunocompromised HostIndividualInfectionInflammatoryInterferonsInvadedKenyaLaboratoriesLicensingLifeLiteratureLivestockMadagascarMass VaccinationsMauritaniaMediatingMembrane FusionMessenger RNAMovementMusMutateMutationMyalgiaNational Institute of Allergy and Infectious DiseaseNeuraxisNeurologicNorth AmericaPanicPatientsPhotophobiaPlayPopulationProductionPropertyProteinsPublic HealthRNARNA chemical synthesisResearchRetinalRetinal VasculitisRift Valley FeverRift Valley fever virusRoleRuminantsSCID MiceSafetySaudi ArabiaSenegalSerial PassageSheepSouth AfricaSpontaneous abortionSystemic infectionTestingTimeVaccinationVaccinesViralViral Envelope ProteinsViral Hemorrhagic FeversViral Nonstructural ProteinsViral ProteinsVirionVirulence FactorsVirusVirus AssemblyVirus DiseasesVirus ReplicationVisual impairmentWild AnimalsYemenbasebiosecuritychemokinecytokineeIF-2 Kinaseeconomic impactimmunogenicimmunogenicityimprovedinnate immune functionintraperitonealmaculamembermouse modelmutantneurovirulencenovelpathogenpreventprogramspromoterprotective efficacyprotein functionsafety testingvaccine candidatevectorviral transmission
项目摘要
DESCRIPTION (provided by applicant): Rift Valley fever virus (RVFV), a prototypical Phlebovirus (family Bunyaviridae), belongs to the NIAID Category A list of pathogens and the CDC list of potential bioterrorism agents. RVFV causes a disease that is endemic in sub-Saharan Africa and can emerge in explosive, mosquito-borne epidemics decimating herds of sheep and cattle, resulting in enormous economic losses. In humans, RVFV infection may cause hemorrhagic fever, encephalitis, and retinal vasculitis. Many different mosquitoes, including several native to North America, are competent vectors for RVFV transmission. Thus, the introduction of RVFV into North America would likely cause panic in the general population, and the effects on livestock could have a devastating economic impact. Induction of a humoral immune response against the viral envelope proteins is necessary and sufficient to provide protection against RVFV. Currently, there is no RVFV vaccine suitable for mass human vaccination programs. The MP-12 strain, which was obtained by 12 serial passages of the wild-type RVFV strain ZH548 in the presence of 5-fluorouracil, is markedly attenuated in mice but retains its immunogenicity. However, intraperitoneal inoculation of MP-12 into young mice or SCID mice results in efficient virus replication in the animals' central nervous system. The neuroinvasiveness and neurovirulence potential of MP-12 is a matter of concern when considering the mass vaccination of the general public, especially, in immunocompromised individuals. The present application proposes the development of a novel and safer MP-12-derived vaccine candidate by introducing mutations in the viral envelope glycoprotein, Gc, and the virulence factor, NSs. The mutation selectively abolishes specific functions of these proteins and creates a "crippled" MP-12. We will test the hypothesis that this MP-12-based vaccine candidate exhibits a better safety profile than MP-12 in mice but still retains its immunogenicity and protective efficacy. In this proposal, we will examine its genetic stability in cultured cells nd assess its safety, immunogenicity, and protective efficacy by using mouse models.
描述(由申请方提供):裂谷热病毒(RVFV)是一种典型的白蛉病毒(布尼亚病毒科),属于NIAID A类病原体列表和CDC潜在生物恐怖主义因子列表。RVFV在撒哈拉以南非洲地区引起一种地方性疾病,并可能以爆炸性的蚊媒流行病出现,大量牛羊死亡,造成巨大的经济损失。在人类中,RVFV感染可引起出血热、脑炎和视网膜血管炎。许多不同的蚊子,包括几种原产于北美的蚊子,都是RVFV传播的有效载体。因此,将RVFV引入北美可能会在普通人群中引起恐慌,对牲畜的影响可能会产生毁灭性的经济影响。诱导针对病毒包膜蛋白的体液免疫应答对于提供针对RVFV的保护是必要且足够的。目前,没有适用于大规模人类疫苗接种计划的RVFV疫苗。在5-氟尿嘧啶存在下,通过野生型RVFV毒株ZH 548的12次连续传代获得的MP-12毒株在小鼠中显著减毒,但保留其免疫原性。然而,将MP-12腹膜内接种到幼龄小鼠或SCID小鼠中导致动物中枢神经系统中的有效病毒复制。MP-12的神经侵袭性和神经毒力潜力是一个值得关注的问题,当考虑大规模接种疫苗的一般公众,特别是在免疫功能低下的个人。本申请提出了通过在病毒包膜糖蛋白Gc和毒力因子NS中引入突变来开发新的且更安全的MP-12衍生疫苗候选物。这种突变选择性地消除了这些蛋白质的特定功能,并产生了一种“残废”的MP-12。我们将检验这一假设,即这种基于MP-12的候选疫苗在小鼠中表现出比MP-12更好的安全性,但仍保留其免疫原性和保护效力。在本研究中,我们将检测其在培养细胞中的遗传稳定性,并使用小鼠模型评估其安全性,免疫原性和保护效力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shinji Makino其他文献
Shinji Makino的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shinji Makino', 18)}}的其他基金
Mechanism of viral RNP recognition by the envelope glycoprotein and its role in RNA segment packaging in Rift Valley Fever phlebovirus
裂谷热白蛉病毒包膜糖蛋白识别病毒RNP的机制及其在RNA片段包装中的作用
- 批准号:
10057583 - 财政年份:2020
- 资助金额:
$ 19.38万 - 项目类别:
Mechanism of viral RNP recognition by the envelope glycoprotein and its role in RNA segment packaging in Rift Valley Fever phlebovirus
裂谷热白蛉病毒包膜糖蛋白识别病毒RNP的机制及其在RNA片段包装中的作用
- 批准号:
10188412 - 财政年份:2020
- 资助金额:
$ 19.38万 - 项目类别:
Interplay between coronaviruses and nonsense-mediated mRNA decay pathway
冠状病毒与无义介导的 mRNA 衰减途径之间的相互作用
- 批准号:
10358595 - 财政年份:2020
- 资助金额:
$ 19.38万 - 项目类别:
Interplay between coronaviruses and nonsense-mediated mRNA decay pathway
冠状病毒与无义介导的 mRNA 衰减途径之间的相互作用
- 批准号:
10614383 - 财政年份:2020
- 资助金额:
$ 19.38万 - 项目类别:
Rational Development of a Novel Attenuated Rift Valley Fever Virus Vaccine
新型裂谷热病毒减毒疫苗的合理研制
- 批准号:
9386475 - 财政年份:2017
- 资助金额:
$ 19.38万 - 项目类别:
New Paradigm for Host and Viral Gene Regulation by MERS Coronavirus nsp1
MERS 冠状病毒 nsp1 宿主和病毒基因调控的新范式
- 批准号:
9189963 - 财政年份:2015
- 资助金额:
$ 19.38万 - 项目类别:
Development of a Novel Rift Valley Fever Virus Vaccine
新型裂谷热病毒疫苗的开发
- 批准号:
8604678 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Development of a Novel Rift Valley Fever Virus Vaccine
新型裂谷热病毒疫苗的开发
- 批准号:
8509347 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Analysis of Coronavirus-Host Cell Interactions
冠状病毒-宿主细胞相互作用分析
- 批准号:
8442842 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
Analysis of Coronavirus-Host Cell Interactions
冠状病毒-宿主细胞相互作用分析
- 批准号:
8888201 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
相似海外基金
ESE: Collaborative Research: Climate Change and Variability and Armed Conflicts in Africa South of the Sahara
ESE:合作研究:撒哈拉以南非洲的气候变化和变异性以及武装冲突
- 批准号:
0964515 - 财政年份:2010
- 资助金额:
$ 19.38万 - 项目类别:
Standard Grant
Network Dynamics, Sexual Behaviour, and HIV Among University Students in Africa South of the Sahara
撒哈拉以南非洲大学生的网络动态、性行为和艾滋病毒
- 批准号:
178094 - 财政年份:2008
- 资助金额:
$ 19.38万 - 项目类别:
Studentship Programs
Synopsis of Ichneumoniae of Africa, South of the Sahara
撒哈拉以南非洲的姬蜂病简介
- 批准号:
66B2956 - 财政年份:1966
- 资助金额:
$ 19.38万 - 项目类别:
To Attend Synopsis of Ichneumoninae of Africa, South of the Sahara
参加撒哈拉以南非洲的姬蜂亚科概要
- 批准号:
65B2956 - 财政年份:1965
- 资助金额:
$ 19.38万 - 项目类别: